1
Yale Digestive Diseases
Temple Medical Center
40 Temple Street, Ste Suite 1A
New Haven, CT 06510
1 of 3
- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510
David N. Assis, MD
Gastroenterology, Hepatology
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Gastroenterology, Internal Medicine
, and Transpant Hepatology
Biography
David Assis, MD, is a hepatologist who treats patients at Yale New Haven Hospital with liver and digestive diseases. He focuses on chronic liver ailments, as well as liver and digestive complications of cystic fibrosis. He tells his patients, “We will support you throughout this process and use cutting-edge discoveries to offer the best possible care.”
Dr. Assis became a hepatologist because he was fascinated by autoimmune liver diseases. An assistant professor of medicine (digestive diseases) at Yale School of Medicine (YSM), he dedicates his research to investigating the causes, mechanisms and treatment of these diseases. In 2014, he was honored with YSM’s Kushlan Junior Faculty Award for his research work.
A member of the America Association for the Study of Liver Diseases, Dr. Assis is optimistic about developing better treatments for patients. “There is much to be discovered in this field, and we expect to see great progress within the next several years,” he says.
Titles
- Associate Professor of Medicine
- Director, Fellowship Program, Digestive Diseases
Education & Training
- FellowshipYale School of Medicine (2013)
- FellowshipYale School of Medicine (2012)
- Chief ResidencyThomas Jefferson University Hospital (2009)
- ResidencyThomas Jefferson University Hospital (2008)
- InternshipThomas Jefferson University, Hospital (2006)
- MDJefferson Medical College (2005)
- BSMessiah College (2001)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
Honors & Recognitions
- Connecticut's Best Doctors 2019: Connecticut Magazine (2019)
Board Certifications
- AB of Internal Medicine, Transpant Hepatology (2014, recertified: 2015)
- AB of Internal Medicine, Internal Medicine (2008, recertified: 2018)
Professional Service
- Hepatology (2013 - Present): Ad hoc reviewer.
Publications
- Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022 PMID: 35838934, DOI: 10.1007/s10753-022-01713-1.
- Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology (Baltimore, Md.) 2022 PMID: 35611859, DOI: 10.1002/hep.32591.
- Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports (Online) 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
- Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
- Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology (Baltimore, Md.) 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
- Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
- Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology (Baltimore, Md.) 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.
- Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.
- Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology And Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
- Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.
- Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.
- Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology (Baltimore, Md.) 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.
- Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.
- Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2020, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.
- Shung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology (Baltimore, Md.) 2020, 71: 8-10. PMID: 31850533, DOI: 10.1002/hep.31069.
- Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.
- Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology (Baltimore, Md.) 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
- Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.
- Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology (Clifton, N.J.) 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
- The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
- Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.
- Assis DN. Chronic Complications of Cholestasis: Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.
- Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2018, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
- Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
- Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis : Official Journal Of The European Cystic Fibrosis Society 2017, 16 Suppl 2: S62-S69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.
- Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/MCG.0000000000000591.
- Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.
- Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns : Journal Of The International Society For Burn Injuries 2016, 42: 1265-76. PMID: 27209369, PMCID: PMC5010466, DOI: 10.1016/j.burns.2016.02.005.
- Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience. Liver International : Official Journal Of The International Association For The Study Of The Liver 2016, 36: 1160-6. PMID: 26763558, DOI: 10.1111/liv.13065.
- Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics In Chest Medicine 2016, 37: 109-18. PMID: 26857772, DOI: 10.1016/j.ccm.2015.11.004.
- Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology (Baltimore, Md.) 2015, 62: 635-43. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
- Assis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD--the story unfolds. Alimentary Pharmacology & Therapeutics 2015, 41: 1214-6. PMID: 25939466, DOI: 10.1111/apt.13186.
- Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (Baltimore, Md.) 2014, 59: 580-91. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
- Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
- Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clinical Pharmacology And Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.
- Assis DN, Pollak J, Schilsky ML, Emre S. Successful treatment of a bleeding umbilical varix by percutaneous umbilical vein embolization with sclerotherapy. Journal Of Clinical Gastroenterology 2012, 46: 115-8. PMID: 21897280, DOI: 10.1097/MCG.0b013e31822b7f9a.
- Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplantation Proceedings 2011, 43: 905-8. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterologica E Dietologica 2010, 56: 331-43. PMID: 21037549.
- Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5: 463-73. PMID: 19416083, DOI: 10.1517/17425250902927386.
- Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54: 670-4. PMID: 18594970, DOI: 10.1007/s10620-008-0376-x.
- Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34: 211-6. PMID: 18219518, DOI: 10.1007/s00261-008-9369-7.
- Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31: 261-70. PMID: 18302450, DOI: 10.2165/00002018-200831030-00007.
- Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364: 155-68. PMID: 17368499, PMCID: PMC3866617, DOI: 10.1016/j.virol.2007.02.007.
Biography
David Assis, MD, is a hepatologist who treats patients at Yale New Haven Hospital with liver and digestive diseases. He focuses on chronic liver ailments, as well as liver and digestive complications of cystic fibrosis. He tells his patients, “We will support you throughout this process and use cutting-edge discoveries to offer the best possible care.”
Dr. Assis became a hepatologist because he was fascinated by autoimmune liver diseases. An assistant professor of medicine (digestive diseases) at Yale School of Medicine (YSM), he dedicates his research to investigating the causes, mechanisms and treatment of these diseases. In 2014, he was honored with YSM’s Kushlan Junior Faculty Award for his research work.
A member of the America Association for the Study of Liver Diseases, Dr. Assis is optimistic about developing better treatments for patients. “There is much to be discovered in this field, and we expect to see great progress within the next several years,” he says.
Titles
- Associate Professor of Medicine
- Director, Fellowship Program, Digestive Diseases
Education & Training
- FellowshipYale School of Medicine (2013)
- FellowshipYale School of Medicine (2012)
- Chief ResidencyThomas Jefferson University Hospital (2009)
- ResidencyThomas Jefferson University Hospital (2008)
- InternshipThomas Jefferson University, Hospital (2006)
- MDJefferson Medical College (2005)
- BSMessiah College (2001)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
Honors & Recognitions
- Connecticut's Best Doctors 2019: Connecticut Magazine (2019)
Board Certifications
- AB of Internal Medicine, Transpant Hepatology (2014, recertified: 2015)
- AB of Internal Medicine, Internal Medicine (2008, recertified: 2018)
Professional Service
- Hepatology (2013 - Present): Ad hoc reviewer.
Publications
- Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022 PMID: 35838934, DOI: 10.1007/s10753-022-01713-1.
- Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology (Baltimore, Md.) 2022 PMID: 35611859, DOI: 10.1002/hep.32591.
- Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports (Online) 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
- Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
- Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology (Baltimore, Md.) 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
- Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
- Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology (Baltimore, Md.) 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.
- Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.
- Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology And Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
- Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.
- Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.
- Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology (Baltimore, Md.) 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.
- Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.
- Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2020, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.
- Shung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology (Baltimore, Md.) 2020, 71: 8-10. PMID: 31850533, DOI: 10.1002/hep.31069.
- Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.
- Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology (Baltimore, Md.) 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
- Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.
- Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology (Clifton, N.J.) 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
- The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
- Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.
- Assis DN. Chronic Complications of Cholestasis: Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.
- Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2018, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
- Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
- Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis : Official Journal Of The European Cystic Fibrosis Society 2017, 16 Suppl 2: S62-S69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.
- Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/MCG.0000000000000591.
- Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.
- Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns : Journal Of The International Society For Burn Injuries 2016, 42: 1265-76. PMID: 27209369, PMCID: PMC5010466, DOI: 10.1016/j.burns.2016.02.005.
- Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience. Liver International : Official Journal Of The International Association For The Study Of The Liver 2016, 36: 1160-6. PMID: 26763558, DOI: 10.1111/liv.13065.
- Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics In Chest Medicine 2016, 37: 109-18. PMID: 26857772, DOI: 10.1016/j.ccm.2015.11.004.
- Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology (Baltimore, Md.) 2015, 62: 635-43. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
- Assis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD--the story unfolds. Alimentary Pharmacology & Therapeutics 2015, 41: 1214-6. PMID: 25939466, DOI: 10.1111/apt.13186.
- Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (Baltimore, Md.) 2014, 59: 580-91. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
- Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
- Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clinical Pharmacology And Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.
- Assis DN, Pollak J, Schilsky ML, Emre S. Successful treatment of a bleeding umbilical varix by percutaneous umbilical vein embolization with sclerotherapy. Journal Of Clinical Gastroenterology 2012, 46: 115-8. PMID: 21897280, DOI: 10.1097/MCG.0b013e31822b7f9a.
- Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplantation Proceedings 2011, 43: 905-8. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterologica E Dietologica 2010, 56: 331-43. PMID: 21037549.
- Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5: 463-73. PMID: 19416083, DOI: 10.1517/17425250902927386.
- Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54: 670-4. PMID: 18594970, DOI: 10.1007/s10620-008-0376-x.
- Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34: 211-6. PMID: 18219518, DOI: 10.1007/s00261-008-9369-7.
- Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31: 261-70. PMID: 18302450, DOI: 10.2165/00002018-200831030-00007.
- Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364: 155-68. PMID: 17368499, PMCID: PMC3866617, DOI: 10.1016/j.virol.2007.02.007.
1
Yale Digestive Diseases
Temple Medical Center
40 Temple Street, Ste Suite 1A
New Haven, CT 06510
1 of 3
- Yale Digestive DiseasesTemple Medical Center40 Temple Street, Ste Suite 1ANew Haven, CT 06510
- Yale Digestive DiseasesYale Health Center55 Lock StreetNew Haven, CT 06511
- Yale Digestive DiseasesYale New Haven Hospital20 York StreetNew Haven, CT 06510